Alec Stranahan
Stock Analyst at B of A Securities
(0.68)
# 3,737
Out of 4,784 analysts
30
Total ratings
36.84%
Success rate
-28.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $22.21 | +89.10% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $4.81 | +149.48% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $5.95 | +152.31% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $8.07 | +209.79% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $0.94 | +1,071.33% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.52 | +228.95% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.20 | +172.73% | 2 | Nov 25, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $37.35 | +47.26% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $7.00 | +157.14% | 3 | Jun 14, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $118 → $140 | $183.92 | -23.88% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $11.23 | +274.00% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $39.86 | -84.95% | 2 | Dec 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $60 → $5 | $1.18 | +323.73% | 1 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $47.41 | -5.08% | 1 | Dec 1, 2022 |
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $22.21
Upside: +89.10%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $4.81
Upside: +149.48%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $5.95
Upside: +152.31%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $8.07
Upside: +209.79%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $0.94
Upside: +1,071.33%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.52
Upside: +228.95%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.20
Upside: +172.73%
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $37.35
Upside: +47.26%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $7.00
Upside: +157.14%
Krystal Biotech
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $183.92
Upside: -23.88%
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $11.23
Upside: +274.00%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $39.86
Upside: -84.95%
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $1.18
Upside: +323.73%
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $47.41
Upside: -5.08%